Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Staser

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Molecules (Basel, Switzerland)|April 27, 2024
Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse ModelSena Kim, Peter Ruminski, Megh Singh, et al.
Experimental Hematology|October 16, 2012
A Pak1-PP2A-ERM signaling axis mediates F-actin rearrangement and degranulation in mast cellsKarl Staser, Matthew A Shew, Elizabeth G Michels, et al.
Experimental Hematology|July 6, 2011
Kinase suppressor of Ras (KSR1) modulates multiple kit-ligand-dependent mast cell functionsMia Chen, Sarah Burgin, Karl Staser, et al.
Plos One|October 1, 2011
Erk1 positively regulates osteoclast differentiation and bone resorptive activityYongzheng He, Karl Staser, Steven D Rhodes, et al.
Leukemia|July 25, 2021
Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFRSena Kim, Kidist Ashami, Sora Lim, et al.
Frontiers in Immunology|September 25, 2023
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant modelsRamzi Abboud, Sena Kim, Karl Staser, et al.
Leukemia|April 26, 2018
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host diseaseJaebok Choi, Matthew L Cooper, Karl Staser, et al.
Stem Cells (Dayton, Ohio)|January 15, 2015
Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiationYi Zeng, Hal E Broxmeyer, Karl Staser, et al.
The Journal of Clinical Investigation|December 11, 2012
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ErkKarl Staser, Su-Jung Park, Steven D Rhodes, et al.
Blood Advances|April 24, 2020
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host diseaseMark A Schroeder, H Jean Khoury, Madan Jagasia, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Molecules (Basel, Switzerland)|April 27, 2024
Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse ModelSena Kim, Peter Ruminski, Megh Singh, et al.
Experimental Hematology|October 16, 2012
A Pak1-PP2A-ERM signaling axis mediates F-actin rearrangement and degranulation in mast cellsKarl Staser, Matthew A Shew, Elizabeth G Michels, et al.
Experimental Hematology|July 6, 2011
Kinase suppressor of Ras (KSR1) modulates multiple kit-ligand-dependent mast cell functionsMia Chen, Sarah Burgin, Karl Staser, et al.
Plos One|October 1, 2011
Erk1 positively regulates osteoclast differentiation and bone resorptive activityYongzheng He, Karl Staser, Steven D Rhodes, et al.
Leukemia|July 25, 2021
Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFRSena Kim, Kidist Ashami, Sora Lim, et al.
Frontiers in Immunology|September 25, 2023
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant modelsRamzi Abboud, Sena Kim, Karl Staser, et al.
Leukemia|April 26, 2018
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host diseaseJaebok Choi, Matthew L Cooper, Karl Staser, et al.
Stem Cells (Dayton, Ohio)|January 15, 2015
Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiationYi Zeng, Hal E Broxmeyer, Karl Staser, et al.
The Journal of Clinical Investigation|December 11, 2012
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ErkKarl Staser, Su-Jung Park, Steven D Rhodes, et al.
Blood Advances|April 24, 2020
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host diseaseMark A Schroeder, H Jean Khoury, Madan Jagasia, et al.
Pageof 3